— Know what they know.
Not Investment Advice

HBIO NASDAQ

Harvard Bioscience, Inc.
1W: +4.8% 1M: +1.7% 3M: +31.3% YTD: +27.9% 1Y: +86.2% 3Y: -80.2% 5Y: -89.1%
$8.34
+0.21 (+2.58%)
 
Weekly Expected Move ±2.8%
$8 $8 $8 $9 $9
NASDAQ · Healthcare · Medical - Instruments & Supplies · Tech Score Buy · Power 66 · $37.6M mcap · 4M float · 0.542% daily turnover · Short 30% of daily vol

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

WEAK EDGE
47.4 / 100
NoneWeakNarrowWide
Primary source: Intangible Assets  ·  ROIC: 1.8%  ·  5Y Avg: -24.9%
Cost Advantage
54
Intangibles
64
Switching Cost
41
Network Effect
29
Scale
40
The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. HBIO shows a Weak competitive edge (47.4/100) — limited structural advantages that may face competitive pressure. The primary source of advantage is Intangible Assets. ROIC of 1.8% suggests modest returns relative to capital deployed.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets
$0
Low
$6
Avg Target
$6
High
Based on 1 analyst ratings (12 mo)
Analyst Recommendations
Strong Buy: 0Buy: 4Hold: 1Sell: 0Strong Sell: 0
Rating Summary
ConsensusBuy
Avg Target$6.00
Analysts1
Price Target Change History
DateFirmAnalystOldNewChangeUpside @ CallStock@Call
2026-03-13 New Street — Initiated $1 — -87.9% $4.94
2024-08-08 KeyBanc Paul Knight Initiated $7 — -77.6% $31.20

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

D+
Oct 02, 2026
DCF
1
ROE
1
ROA
1
D/E
1
P/E
1
P/B
2
The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. HBIO receives an overall rating of D+. Areas of concern: DCF (1/5), ROE (1/5), ROA (1/5), D/E (1/5), P/E (1/5), P/B (2/5).
Rating Change History
DateFromTo
2026-08-11 C- D+
2026-05-12 D+ C-
2026-05-12 C- D+
2026-03-17 D+ C-
2026-03-16 C D+
2026-03-13 C- C
2026-03-12 C+ C-
2026-03-09 C C+
2026-02-10 C+ C
2026-01-12 C C+

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

★ ★ ★ ★ ★ 20 Grade D
Profitability
17
Balance Sheet
29
Earnings Quality
38
Growth
67
Value
20
Momentum
64
Safety
0
Cash Flow
12
The InsiderStreet Scorecard rates companies across eight dimensions: Profitability (margins, ROA, ROE), Balance Sheet (leverage, liquidity, coverage), Earnings Quality (accruals, cash conversion), Growth (revenue and earnings trajectory), Value (P/E, P/B, earnings yield, Graham criteria), Momentum (revenue and earnings acceleration), Safety (Altman Z-Score risk adjustment), and Cash Flow (operating cash flow quality, FCF conversion, cash coverage). The overall score blends 35% quality, 35% value, and 30% momentum, with a penalty for distress-zone Altman scores. HBIO scores highest in Growth (67/100) and lowest in Safety (0/100). A grade of D flags significant fundamental concerns across multiple dimensions.

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score
-2.63
Distress Zone
Piotroski F-Score
7/9
✗ ✓ ✓ ✓ ✗ ✓ ✓ ✓ ✓
Beneish M-Score
-3.10
Unlikely Manipulator
Ohlson O-Score
-3.39
Bankruptcy prob: 3.3%
Low Risk
Credit Rating
CCC
Score: 17.4/100
Trend: Improving
Earnings Quality
—
OCF/NI: -0.04x
Accruals: -13.8%
The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. HBIO scores -2.63, placing it in the Distress Zone (safe > 2.99, distress < 1.81). Historically, companies in this range face elevated bankruptcy risk. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. HBIO scores 7/9, signaling strong financial health across all three dimensions. The Beneish M-Score (1999) is an 8-variable model that detects earnings manipulation by comparing year-over-year changes in receivables, gross margins, asset quality, sales growth, depreciation, SG&A, leverage, and accruals. Scores above −1.78 statistically resemble past manipulators. HBIO's score of -3.10 falls below this threshold, suggesting earnings are unlikely to be manipulated. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. HBIO's implied 3.3% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. HBIO receives an estimated rating of CCC (score: 17.4/100), with a improving trend.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E
-3.59x
PEG
-0.05x
P/S
0.43x
P/B
5.09x
P/FCF
-18.25x
P/OCF
70.47x
EV/EBITDA
-69.80x
EV/Revenue
0.75x
EV/EBIT
-9.16x
EV/FCF
-42.98x
Earnings Yield
-37.41%
FCF Yield
-5.48%
Shareholder Yield
0.00%
Graham Number
—
Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. HBIO currently has negative earnings — the P/E ratio is not meaningful.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden
0.988
NI / EBT
×
Interest Burden
1.474
EBT / EBIT
×
EBIT Margin
-0.081
EBIT / Rev
×
Asset Turnover
1.123
Rev / Assets
×
Equity Multiplier
6.755
Assets / Equity
=
ROE
-89.9%
The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. HBIO's ROE of -89.9% is driven by financial leverage (equity multiplier: 6.75x). Note: high leverage means ROE is amplified by debt rather than operational performance. A tax burden ratio of 0.99 indicates minimal tax leakage — the company retains over 90% of pre-tax earnings.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Two adjustments we make, and why. Growth is capped at 15%. Graham defined g as expected growth over the next seven to ten years, not last year's rate. Across US companies since 1994 the median realized 7-year EPS growth is 5–8% regardless of how fast a company grew beforehand, and of 4,457 company-quarters that grew faster than 200%, none sustained it. Uncapped, the formula assigned fair multiples in the hundreds to companies that had never held that rate — and scored worse than simply reading the P/E. Capped, it carries real information. The verdict has three states, not two. Tested over 377,249 stock-months, this ratio only separates outcomes at its extremes: below 0.25 beat the universe by 1.3 points a year, above 3.0 lagged by 2.7, and everything in between sat inside a one-point band. Rather than call two-thirds of the market "undervalued" on a threshold of 1.0, we say Neutral where the model cannot tell — which is most of the time.

Adj. Growth Rate
0.00%
Fair P/E
8.50x
Intrinsic Value
—
Price/Value
—
Margin of Safety
—
Premium
—

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1800 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$8.34
Median 1Y
$5.37
5th Pctile
$1.43
95th Pctile
$20.04
Ann. Volatility
77.5%
25th–75th percentile 5th–95th percentile Median path Historical

Executive Compensation

C-suite compensation breakdown including salary, stock awards, options, and incentive pay. The CEO-to-employee pay ratio and Gini coefficient measure pay distribution fairness.

C-Suite Compensation

ExecutiveSalaryStockTotal
John Duke &
resident & Chief Executive Officer
$203,077 $598,900 $905,208
James W. Green
Former Chairman, President & Chief Executive Officer
$336,923 $— $355,823
Mark Frost Financial
ancial Officer & Treasurer
$201,846 $35,210 $343,518
Jennifer Cote Financial
ief Financial Officer and Treasurer
$118,846 $— $123,006

CEO Pay Ratio

8:1
CEO-to-Employee Pay Ratio
CEO Total Comp: $905,208
Avg Employee Cost (SGA/emp): $116,956
Employees: 316

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees
316
-4.2% YoY
Revenue / Employee
$273,892
Rev: $86,550,000
Profit / Employee
$-179,430
NI: $-56,700,000
SGA / Employee
$116,956
Avg labor cost proxy
R&D / Employee
$27,927
Innovation spend

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
ROE -2.4% -0.4% -8.5% -4.7% -9.3% -12.2% -2.7% -7.1% -4.5% -4.7% -12.2% -15.0% -20.4% -18.2% -1.4% -1.4% -1.4% -1.5% -78.6% -89.9% -89.95%
ROA -1.2% -0.2% -4.2% -2.4% -4.6% -6.2% -1.3% -3.6% -2.3% -2.4% -6.3% -7.9% -10.5% -9.4% -54.5% -54.9% -51.5% -54.9% -12.4% -13.3% -13.32%
ROIC 2.0% 1.2% -2.7% -0.3% -3.0% -4.5% 1.0% -1.1% 0.8% 1.3% -1.6% -3.8% -4.4% -4.7% -78.6% -80.1% -79.4% -77.3% 2.0% 1.8% 1.80%
ROCE 0.3% 1.0% -3.8% -0.6% -4.1% -5.4% 1.4% -2.8% 0.8% 0.5% -4.5% -5.9% -9.4% -11.8% -2.3% -2.2% -2.1% -90.3% -13.9% -13.9% -13.89%
Gross Margin 55.0% 59.2% 56.2% 57.0% 45.2% 55.7% 61.2% 58.0% 58.1% 53.1% 60.3% 57.2% 58.1% 57.1% 56.0% 50.7% 58.4% 59.7% 59.0% 55.6% 55.57%
Operating Margin 1.8% 5.1% -23.3% 13.7% -14.0% -1.6% 5.8% 2.8% -3.7% 1.0% -9.3% -9.0% -8.5% 0.0% -2.3% -4.0% 1.0% 8.1% -0.6% -4.3% -4.30%
Net Margin -0.6% 2.9% -23.9% 8.3% -12.6% -5.9% 2.1% -3.4% -4.9% -6.5% -19.1% -12.7% -21.9% 0.1% -2.3% -11.2% -6.0% -12.0% -16.5% -12.8% -12.80%
EBITDA Margin 7.7% 10.4% -16.6% 19.7% -7.4% 6.9% 11.6% 2.0% 8.3% 5.2% -8.0% -3.2% -8.3% 13.0% -2.2% 0.8% 5.6% 2.1% -17.8% 4.8% 4.78%
FCF Margin 2.2% -0.1% -2.7% -3.7% -2.6% -0.4% 3.1% 6.4% 9.8% 10.5% 10.2% 6.2% 0.3% -1.8% 0.1% 4.8% 7.9% 5.7% 1.6% -1.7% -1.74%
OCF Margin 3.1% 1.1% -1.5% -2.3% -1.2% 1.0% 4.3% 7.6% 11.0% 12.5% 12.8% 9.1% 4.1% 1.5% 3.3% 7.5% 9.5% 7.5% 3.3% 0.4% 0.45%
ROE 3Y Avg snapshot only -1.74%
ROE 5Y Avg snapshot only -1.07%
ROA 3Y Avg snapshot only -31.20%
ROIC 3Y Avg snapshot only -30.66%
ROIC Economic snapshot only 1.63%
Cash ROA snapshot only 0.52%
Cash ROIC snapshot only 0.88%
CROIC snapshot only -3.38%
NOPAT Margin snapshot only 0.92%
Pretax Margin snapshot only -12.00%
R&D / Revenue snapshot only 10.36%
SGA / Revenue snapshot only 43.34%
SBC / Revenue snapshot only 0.82%
Valuation
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
P/E Ratio -1526.09 -10617.10 -393.86 -419.31 -154.73 -122.55 -892.20 -428.30 -562.54 -669.10 -210.77 -116.07 -82.38 -74.05 -4.30 -3.43 -0.36 -0.52 -2.23 -2.67 -3.586
P/S Ratio 24.35 25.72 21.21 12.69 9.04 10.29 15.69 20.38 16.31 20.36 17.23 12.26 12.00 9.76 2.73 2.22 0.22 0.34 0.25 0.32 0.428
P/B Ratio 37.00 36.66 33.51 19.77 14.81 16.15 24.17 30.84 24.71 31.27 26.74 18.43 17.96 14.50 16.82 12.50 1.39 2.16 2.17 3.75 5.089
P/FCF 1100.86 -36840.07 -781.35 -342.77 -341.31 -2662.62 498.17 319.66 166.46 193.23 168.52 199.22 3809.14 -548.45 2170.29 45.73 2.84 6.03 15.99 -18.25 -18.252
P/OCF 782.57 2422.92 — — — 1012.35 363.01 267.51 147.98 162.89 135.12 134.41 291.99 637.95 82.56 29.70 2.36 4.59 7.71 70.47 70.468
EV/EBITDA 359.13 344.40 1004.83 236.15 464.34 1288.09 200.46 592.57 231.49 305.84 863.15 1449.21 -399.72 -738.29 -6.05 -4.97 -1.27 -1.40 -31.45 -69.80 -69.795
EV/Revenue 24.76 26.13 21.64 13.13 9.47 10.73 16.10 20.77 16.67 20.70 17.58 12.63 12.43 10.19 3.16 2.62 0.64 0.76 0.69 0.75 0.746
EV/EBIT 6635.63 2219.19 -526.41 -2057.53 -217.91 -183.37 1052.64 -709.10 2038.62 3853.19 -384.78 -204.18 -118.96 -113.42 -5.28 -4.34 -1.11 -1.25 -7.83 -9.16 -9.164
EV/FCF 1119.63 -37432.11 -797.17 -354.43 -357.89 -2776.16 511.29 325.70 170.09 196.49 171.92 205.23 3942.66 -572.56 2509.95 54.08 8.07 13.28 43.18 -42.98 -42.976
Earnings Yield -0.1% -0.0% -0.3% -0.2% -0.6% -0.8% -0.1% -0.2% -0.2% -0.1% -0.5% -0.9% -1.2% -1.4% -23.3% -29.2% -2.8% -1.9% -44.9% -37.4% -37.41%
FCF Yield 0.1% -0.0% -0.1% -0.3% -0.3% -0.0% 0.2% 0.3% 0.6% 0.5% 0.6% 0.5% 0.0% -0.2% 0.0% 2.2% 35.2% 16.6% 6.3% -5.5% -5.48%
EV/OCF snapshot only 165.919
EV/Gross Profit snapshot only 1.283
Acquirers Multiple snapshot only 63.815
Shareholder Yield snapshot only 0.00%
Leverage & Solvency
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Current Ratio 2.37 2.43 2.18 2.42 2.43 2.20 2.26 2.29 2.09 1.85 1.88 2.05 2.06 0.82 0.81 0.81 0.81 2.20 1.99 1.87 1.874
Quick Ratio 1.26 1.34 1.13 1.16 1.20 1.06 1.10 1.16 1.02 0.92 0.94 0.94 0.91 0.40 0.40 0.41 0.41 1.25 1.06 0.98 0.977
Debt/Equity 0.70 0.68 0.75 0.73 0.79 0.75 0.69 0.64 0.61 0.59 0.60 0.62 0.70 0.70 3.01 2.75 3.04 3.22 4.39 5.96 5.959
Net Debt/Equity 0.63 0.59 0.68 0.67 0.72 0.69 0.64 0.58 0.54 0.53 0.54 0.56 0.63 0.64 2.63 2.28 2.56 2.60 3.69 5.08 5.083
Debt/Assets 0.35 0.35 0.36 0.36 0.39 0.37 0.35 0.34 0.32 0.31 0.31 0.32 0.35 0.35 0.56 0.54 0.55 0.55 0.57 0.58 0.579
Debt/EBITDA 6.71 6.31 22.04 8.41 23.65 57.46 5.56 12.06 5.59 5.63 19.02 47.05 -15.04 -34.25 -0.94 -0.93 -0.98 -0.95 -23.59 -47.08 -47.078
Net Debt/EBITDA 6.02 5.45 19.95 7.77 21.51 52.68 5.14 10.97 4.93 5.07 17.06 42.46 -13.54 -31.09 -0.82 -0.77 -0.82 -0.77 -19.80 -40.15 -40.152
Interest Coverage 0.19 0.91 -3.28 -0.47 -2.53 -2.60 0.56 -0.94 0.25 0.17 -1.45 -1.97 -3.24 -2.64 -16.78 -16.25 -14.71 -10.67 -3.15 -2.11 -2.110
Equity Multiplier 2.00 1.95 2.07 2.00 2.04 2.01 1.96 1.90 1.88 1.88 1.94 1.92 2.01 2.00 5.38 5.09 5.54 5.83 7.76 10.28 10.284
Cash Ratio snapshot only 0.262
Debt Service Coverage snapshot only -0.277
Cash to Debt snapshot only 0.147
FCF to Debt snapshot only -0.034
Defensive Interval snapshot only 153.2 days
Efficiency & Turnover
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Asset Turnover 0.77 0.75 0.78 0.78 0.78 0.74 0.75 0.77 0.78 0.79 0.77 0.74 0.72 0.71 0.86 0.85 0.84 0.84 1.08 1.12 1.123
Inventory Turnover 2.10 2.06 2.04 1.93 2.05 1.94 1.86 1.84 1.81 1.86 1.79 1.70 1.62 1.64 1.67 1.66 1.63 1.72 1.63 1.65 1.652
Receivables Turnover 7.25 6.01 6.46 6.85 7.07 5.88 6.03 6.57 7.50 6.84 6.46 6.88 7.03 6.08 6.35 7.27 7.01 5.60 6.10 6.64 6.643
Payables Turnover 8.79 9.42 8.28 7.28 9.30 9.25 8.45 8.86 7.73 7.93 7.60 8.34 7.28 7.61 7.23 7.56 7.42 8.96 7.28 6.71 6.713
DSO 50 61 56 53 52 62 61 56 49 53 56 53 52 60 57 50 52 65 60 55 54.9 days
DIO 174 178 179 190 178 188 197 198 202 196 204 215 225 222 218 219 224 213 224 221 221.0 days
DPO 42 39 44 50 39 39 43 41 47 46 48 44 50 48 50 48 49 41 50 54 54.4 days
Cash Conversion Cycle 183 200 192 193 190 210 214 212 203 204 212 224 227 234 225 221 227 237 233 222 221.5 days
Fixed Asset Turnover snapshot only 7.475
Operating Cycle snapshot only 275.9 days
Cash Velocity snapshot only 13.503
Capital Intensity snapshot only 0.869
Growth (YoY)
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Revenue 14.4% 16.5% 14.6% 8.5% 1.0% -4.7% -5.1% -5.5% -4.6% -1.0% -6.8% -11.4% -13.1% -16.1% -14.4% -12.2% -10.6% -8.1% -6.4% -1.1% -1.06%
Net Income 71.9% 96.3% -64.0% -30.9% -2.7% -32.0% 69.0% -48.6% 52.6% 64.1% -3.3% -96.7% -3.4% -2.6% -5.6% -4.4% -2.8% -3.6% 83.1% 81.9% 81.86%
EPS 73.2% 96.7% -58.3% -23.5% -2.6% -33.0% 70.1% -49.3% 53.8% 64.6% -3.3% -91.6% -3.3% -2.6% -5.5% -4.3% -36.0% -43.8% -66.2% -77.5% -77.54%
FCF -65.7% -1.0% -1.5% -1.9% -2.2% -4.3% 2.1% 2.6% 4.5% 28.0% 2.0% -14.5% -97.2% -1.1% -98.9% -30.9% 21.3% 3.9% 10.8% -1.4% -1.35%
EBITDA 33.6% 74.5% -67.7% -9.3% -70.1% -89.5% 2.5% -40.4% 2.4% 7.0% -76.4% -78.0% -1.4% -1.2% -22.9% -54.1% -13.4% -34.8% 96.1% 98.0% 97.99%
Op. Income 4.5% 8.3% -2.4% -1.2% -2.5% -4.4% 1.3% -2.6% 1.2% 1.3% -2.4% -2.0% -6.1% -4.3% -24.1% -9.5% -7.5% -6.8% 1.0% 1.0% 1.02%
OCF Growth snapshot only -94.04%
Asset Growth snapshot only -4.75%
Equity Growth snapshot only -52.85%
Debt Growth snapshot only 2.06%
Shares Change snapshot only -89.78%
Growth (CAGR)
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Revenue 3Y 0.7% -0.5% -0.4% 0.1% -0.3% -0.8% 0.8% 2.7% 3.3% 3.2% 0.5% -3.1% -5.8% -7.5% -8.9% -9.7% -9.5% -8.6% -9.3% -8.4% -8.36%
Revenue 5Y 1.9% 2.6% 3.5% 3.7% 3.2% 2.2% 1.9% 0.6% -0.3% -1.5% -2.7% -3.4% -3.9% -4.1% -3.9% -3.4% -3.1% -3.3% -4.1% -4.6% -4.61%
EPS 3Y — — — — — — — — — — — — — — — — — — — — —
EPS 5Y — — — — — — — — — — — — — — — — — — — — —
Net Income 3Y — — — — — — — — — — — — — — — — — — — — —
Net Income 5Y — — — — — — — — — — — — — — — — — — — — —
EBITDA 3Y 52.6% 24.0% -34.0% -10.0% -29.2% -47.9% 33.7% -3.8% 10.3% 13.7% -35.4% -50.8% — — — — — — — — —
EBITDA 5Y 25.8% 42.2% 26.9% 40.8% 10.8% -15.9% — 63.2% 29.0% 9.9% -24.8% -37.4% — — — — — — — — —
Gross Profit 3Y 4.5% 2.3% 1.2% 1.0% -0.7% -1.8% 1.0% 2.2% 4.4% 3.7% 0.3% -2.9% -5.4% -6.8% -8.6% -10.4% -9.0% -7.1% -8.2% -6.8% -6.77%
Gross Profit 5Y 6.0% 6.9% 7.8% 8.1% 6.8% 5.0% 5.0% 3.4% 2.6% 0.5% -1.5% -2.9% -3.3% -3.2% -3.1% -3.5% -3.3% -3.4% -4.2% -4.1% -4.11%
Op. Income 3Y — 28.0% — — — — — — — 1.0% — — — — — — — — -8.1% — —
Op. Income 5Y — — — — — — — — — 14.0% — — — — — — — — -18.3% -17.9% -17.92%
FCF 3Y — — — — — — -22.0% -7.9% 13.5% 13.1% 20.2% 9.4% -50.8% — — — — — -27.7% — —
FCF 5Y -7.4% — — — — — 31.8% 32.1% — 44.5% 23.5% 15.3% -47.3% — -56.7% -14.3% -1.8% -9.7% -26.3% — —
OCF 3Y — -24.1% — — — -47.7% -17.8% -7.1% 11.0% 14.6% 22.0% 16.1% 3.4% 4.5% — — — 77.8% -17.0% -64.3% -64.31%
OCF 5Y -7.7% -25.2% — — — 1.7% 18.5% 24.4% — 37.2% 25.1% 20.8% -13.7% -29.1% -19.4% -9.4% -1.7% -7.0% -17.7% -41.8% -41.75%
Assets 3Y -2.3% -1.1% -2.7% -2.3% -3.3% -4.1% -2.3% -1.8% -2.3% -4.2% -4.2% -5.7% -5.2% -7.9% -20.4% -19.8% -19.0% -18.0% -18.8% -18.9% -18.88%
Assets 5Y 6.5% 8.5% 8.0% 7.4% 5.8% 5.9% -3.2% -2.8% -3.3% -4.0% -4.9% -5.0% -4.2% -5.1% -12.6% -11.9% -12.2% -12.5% -12.4% -13.1% -13.10%
Equity 3Y -1.7% 0.5% -1.7% -1.2% -2.3% -4.0% -0.7% -0.3% -1.3% -1.6% -3.7% -5.1% -5.3% -8.8% -42.1% -41.2% -42.0% -42.5% -48.7% -53.8% -53.83%
Book Value 3Y -4.9% -4.4% -4.6% -5.1% -5.2% -7.3% -4.3% -3.4% -4.3% -4.6% -6.5% -7.6% -7.4% -8.9% -43.4% -42.0% 22.2% 21.7% 8.9% -2.7% -2.71%
Dividend 3Y — — — — — — — — — — — — — — — — — — — — —
Growth Quality
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Revenue Stability 0.06 0.07 0.21 0.37 0.37 0.31 0.48 0.30 0.05 0.05 0.25 0.47 0.62 0.56 0.45 0.31 0.27 0.33 0.54 0.77 0.773
Earnings Stability 0.42 0.00 0.16 0.00 0.12 0.28 0.00 0.02 0.00 0.01 0.19 0.39 0.37 0.18 0.44 0.47 0.53 0.49 0.23 0.27 0.271
Margin Stability 0.92 0.92 0.92 0.92 0.92 0.92 0.93 0.93 0.95 0.96 0.97 0.98 0.98 0.97 0.98 0.99 0.98 0.97 0.98 0.98 0.979
Rev. Growth Consistency 0.50 0.50 0.50 1.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000
Earn. Growth Consistency 0.50 0.50 0.00 0.00 0.00 0.00 0.50 0.00 0.50 0.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.50 0.50 0.500
FCF Positive Streak 1 0 0 0 0 0 0 0 0 0 1 1 1 0 1 1 1 0 1 0 0
Earnings Persistence 0.50 0.50 0.50 0.88 0.50 0.50 0.50 0.81 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.500
Earnings Smoothness — — — — — — — — — — — — — — — — — — — — —
ROE Trend 0.04 0.08 -0.01 0.02 -0.04 -0.08 0.04 -0.03 0.02 0.02 -0.07 -0.10 -0.15 -0.11 -3.84 -3.53 -3.70 -4.01 1.05 0.50 0.500
Gross Margin Trend 0.00 0.01 0.01 0.01 -0.02 -0.03 -0.02 -0.02 0.03 0.02 0.01 0.01 0.00 0.03 0.01 -0.01 -0.02 -0.02 -0.00 0.02 0.019
FCF Margin Trend -0.05 -0.07 -0.09 -0.10 -0.07 -0.04 0.02 0.06 0.10 0.11 0.10 0.05 -0.03 -0.07 -0.07 -0.01 0.03 0.01 -0.04 -0.07 -0.072
Sustainable Growth Rate — — — — — — — — — — — — — — — — — — — — —
Internal Growth Rate — — — — — — — — — — — — — — — — — — — — —
Cash Flow Quality
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
OCF/Net Income -1.95 -4.38 0.27 0.74 0.20 -0.12 -2.46 -1.60 -3.80 -4.11 -1.56 -0.86 -0.28 -0.12 -0.05 -0.12 -0.15 -0.11 -0.29 -0.04 -0.038
FCF/OCF 0.71 -0.07 1.86 1.64 2.21 -0.38 0.73 0.84 0.89 0.84 0.80 0.67 0.08 -1.16 0.04 0.65 0.83 0.76 0.48 -3.86 -3.861
FCF/Net Income snapshot only 0.146
CapEx/Revenue 0.9% 1.1% 1.3% 1.5% 1.5% 1.4% 1.2% 1.2% 1.2% 2.0% 2.5% 3.0% 3.8% 3.3% 3.2% 2.6% 1.6% 1.8% 1.7% 2.2% 2.19%
CapEx/Depreciation snapshot only 0.309
Accruals Ratio -0.04 -0.01 -0.03 -0.01 -0.04 -0.07 -0.05 -0.09 -0.11 -0.12 -0.16 -0.15 -0.13 -0.10 -0.57 -0.61 -0.59 -0.61 -0.16 -0.14 -0.138
Sloan Accruals snapshot only 0.329
Cash Flow Adequacy snapshot only 0.206
Dividends & Buybacks
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Dividend Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Dividend/Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.01 $0.01 $0.01 $0.01 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Payout Ratio — — — — — — — — — — — — — — — — — — — — —
FCF Payout Ratio 0.0% — — — — — 0.0% 0.0% 0.0% 4.1% 4.4% 7.7% 1.6% — 0.0% 0.0% 0.0% 0.0% 0.0% — —
Total Payout Ratio — — — — — — — — — — — — — — — — — — — — —
Div. Increase Streak — — — — — — — — — 0 0 0 0 — — — — — — — —
Chowder Number — — — — — — — — — — — — — — — — — — — — —
Buyback Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.4% 0.3% 0.0% 0.0% 0.00%
Net Buyback Yield 0.0% 0.0% 0.0% -0.0% -0.0% 0.0% 0.0% 0.0% 0.0% -0.0% 0.0% -0.0% -0.0% -0.0% -0.0% 0.0% 0.4% 0.2% -0.7% -0.5% -0.54%
Total Shareholder Return 0.0% 0.0% 0.0% -0.0% -0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% -0.0% -0.0% 0.0% 0.4% 0.2% -0.7% -0.5% -0.54%
DuPont Factors
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Tax Burden (NI/EBT) 1.02 2.06 1.00 1.51 0.96 1.04 2.11 0.84 1.39 1.34 1.06 1.13 1.07 1.06 1.00 1.01 1.00 0.99 0.99 0.99 0.988
Interest Burden (EBT/EBIT) -4.17 -0.10 1.30 3.14 1.40 1.38 -0.54 1.94 -2.55 -4.24 1.69 1.51 1.31 1.38 1.06 1.06 1.07 1.09 1.32 1.47 1.474
EBIT Margin 0.00 0.01 -0.04 -0.01 -0.04 -0.06 0.02 -0.03 0.01 0.01 -0.05 -0.06 -0.10 -0.09 -0.60 -0.60 -0.57 -0.61 -0.09 -0.08 -0.081
Asset Turnover 0.77 0.75 0.78 0.78 0.78 0.74 0.75 0.77 0.78 0.79 0.77 0.74 0.72 0.71 0.86 0.85 0.84 0.84 1.08 1.12 1.123
Equity Multiplier 1.97 1.99 2.02 1.98 2.02 1.98 2.01 1.95 1.96 1.95 1.95 1.91 1.94 1.94 2.55 2.52 2.64 2.68 6.34 6.75 6.755
Per Share
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
EPS (Diluted TTM) $-0.05 $-0.01 $-0.16 $-0.09 $-0.17 $-0.23 $-0.05 $-0.13 $-0.08 $-0.08 $-0.20 $-0.25 $-0.33 $-0.28 $-1.32 $-1.30 $-12.08 $-12.77 $-2.19 $-2.30 $-2.30
Book Value/Share $1.89 $1.92 $1.85 $1.82 $1.73 $1.72 $1.74 $1.78 $1.74 $1.71 $1.59 $1.55 $1.50 $1.45 $0.34 $0.36 $3.16 $3.09 $2.25 $1.64 $1.64
Tangible Book/Share $-0.25 $-0.04 $-0.17 $-0.07 $-0.13 $-0.12 $-0.04 $0.01 $0.02 $-0.00 $-0.06 $-0.06 $-0.10 $-0.09 $-0.10 $-0.08 $-0.86 $-0.78 $-1.39 $-1.80 $-1.80
Revenue/Share $2.87 $2.74 $2.93 $2.84 $2.83 $2.69 $2.68 $2.69 $2.64 $2.63 $2.46 $2.33 $2.24 $2.16 $2.07 $2.00 $19.61 $19.50 $19.12 $19.40 $19.40
FCF/Share $0.06 $-0.00 $-0.08 $-0.11 $-0.08 $-0.01 $0.08 $0.17 $0.26 $0.28 $0.25 $0.14 $0.01 $-0.04 $0.00 $0.10 $1.54 $1.11 $0.30 $-0.34 $-0.31
OCF/Share $0.09 $0.03 $-0.04 $-0.06 $-0.03 $0.03 $0.12 $0.21 $0.29 $0.33 $0.31 $0.21 $0.09 $0.03 $0.07 $0.15 $1.86 $1.46 $0.63 $0.09 $0.14
Cash/Share $0.14 $0.18 $0.13 $0.10 $0.12 $0.11 $0.09 $0.10 $0.13 $0.10 $0.10 $0.09 $0.10 $0.09 $0.13 $0.17 $1.53 $1.94 $1.59 $1.44 $1.44
EBITDA/Share $0.20 $0.21 $0.06 $0.16 $0.06 $0.02 $0.22 $0.09 $0.19 $0.18 $0.05 $0.02 $-0.07 $-0.03 $-1.08 $-1.06 $-9.84 $-10.48 $-0.42 $-0.21 $-0.21
Debt/Share $1.33 $1.31 $1.39 $1.33 $1.37 $1.29 $1.19 $1.14 $1.06 $1.00 $0.95 $0.95 $1.05 $1.02 $1.01 $0.98 $9.60 $9.97 $9.86 $9.77 $9.77
Net Debt/Share $1.19 $1.13 $1.26 $1.23 $1.24 $1.18 $1.11 $1.04 $0.94 $0.90 $0.86 $0.86 $0.94 $0.93 $0.89 $0.81 $8.07 $8.03 $8.28 $8.33 $8.33
Academic Models
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Altman Z-Score — — — — — — — — — — — — — — — — — — — — -2.632
Altman Z-Prime snapshot only -7.788
Piotroski F-Score 6 6 2 4 3 4 6 5 5 5 3 3 3 3 3 3 5 6 6 7 7
Beneish M-Score -2.38 -2.38 -2.47 -2.50 -2.74 -3.04 -2.86 -3.02 -3.14 -3.10 -3.43 -3.52 -3.31 -3.14 -6.54 -6.56 -6.66 -6.45 -3.26 -3.10 -3.096
Ohlson O-Score snapshot only -3.392
Net-Net WC snapshot only $-4.95
EVA snapshot only $-3700770.00
Credit
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Credit Rating snapshot only CCC
Credit Score 46.56 47.18 44.39 46.04 45.86 47.41 52.44 50.42 56.99 53.88 50.45 49.81 54.42 46.59 14.79 16.25 16.97 22.98 19.60 17.41 17.408
Credit Grade snapshot only 17
Credit Trend snapshot only 1.161
Implied Spread (bps) snapshot only 1200.000
Industry Credit Rank snapshot only 5
Sector Credit Rank snapshot only 8

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms